Filtered By:
Cancer: Cancer
Therapy: Radiation Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 7655 results found since Jan 2013.
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
DISCUSSION: This trial will help define the best neoadjuvant treatment sequence for borderline resectable PDAC and aims to evaluate if a total neoadjuvant treatment integrating iHD-SBRT improves the patients' oncological outcomes.TRIAL REGISTRATION: The study was registered at ClinicalTrails.gov (NCT05083247) on October 19th, 2021, and in the Clinical Trials Information System (CTIS) EU CT database (2022-501181-22-01) on July 2022.PMID:37735634 | DOI:10.1186/s12885-023-11327-x
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Christelle Bouchart Julie Navez Ivan Borbath Karen Geboes Timon Vandamme Jean Closset Luigi Moretti Pieter Demetter Marianne Paesmans Jean-Luc Van Laethem Source Type: research
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)
CONCLUSION: The trial reached its primary end point of biochemical control and PFS, suggesting a clinical advantage for SBRT in addition to first-line AAP treatment in patients with metastatic castration-resistant prostate cancer.PMID:37733977 | DOI:10.1200/JCO.23.00985
Source: Clinical Prostate Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Giulio Francolini Andrea Gaetano Allegra Beatrice Detti Vanessa Di Cataldo Saverio Caini Alessio Bruni Gianluca Ingrosso Rolando Maria D'Angelillo Anna Rita Alitto Matteo Augugliaro Luca Triggiani Silvana Parisi Gaetano Facchini Marco Banini Gabriele Simo Source Type: research
Interprofessional Approach to Fall Risk Screening in Patients Undergoing Radiation Therapy
Clin J Oncol Nurs. 2023 Sep 15;27(5):565-570. doi: 10.1188/23.CJON.565-570.ABSTRACTPatients receiving radiation therapy (RT) for cancer are at greater risk for falls because of age, treatment, pharmacologic side effects, and cognitive or motor deficits. The Timed Up and Go (TUG) Test is a validated, objecti.PMID:37729459 | DOI:10.1188/23.CJON.565-570
Source: Clinical Journal of Oncology Nursing - September 20, 2023 Category: Nursing Authors: Amy Martinez Jason Baxley Emery Bergey Ron Jennings Cassandra Vonnes Source Type: research
Analysis of Prognoses according to Breast MRI Results in Patients with Axillary Lymph Node Metastases from an Unknown Primary Origin
CONCLUSION: The prognoses of MR-negative patients with ACUPax who received ALND and WBRT followed by chemotherapy were as good as those of patients with MRI-detected primary breast cancers.PMID:37727923 | DOI:10.3349/ymj.2023.0181
Source: Yonsei Medical Journal - September 20, 2023 Category: Universities & Medical Training Authors: E-Ryung Choi Ok Hee Woo Eun Young Ko Boo-Kyung Han Ji Soo Choi Eun Sook Ko Haejung Kim Myoung Kyoung Kim Jeong Eon Lee Source Type: research
Endometrial adenocarcinoma recurring in the lung: impact of molecular profile and role of local therapies on prognosis
CONCLUSION: Although few patients will benefit from local treatment (stereotactic body radiation therapy or resection) after a recurrence involving the lung, local therapies might be considered as an option in oligometastatic lung recurrences as they achieve high local control rates and better oncological outcomes than systemic treatment alone.PMID:37726197 | DOI:10.1136/ijgc-2023-004534
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Ana Luzarraga Aznar Vicente Bebia Carlos L ópez-Gil Alexandra Giraldo M P Montoya Ramona Verges Alberto Jauregui Josep Castellvi Assumpci ó Pérez-Benavente Eva Col ás Antonio Gil-Moreno Silvia Cabrera Source Type: research
Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer
CONCLUSIONS: Our results suggest that GG 1 patients already show a low level of failure at a standard dose of 77 Gy, limiting the additional benefit of focal boosting. In contrast, patients with high-risk characteristics, especially GG 4 or 5, show a low 5-year DFS, while focal boosting might improve this substantially. This suggests that reaching a high focal boost dose may be particularly beneficial for these patients.PMID:37725026 | DOI:10.1016/j.ijrobp.2023.07.044
Source: Health Physics - September 19, 2023 Category: Physics Authors: Karol ína Menne Guricová Veerle Groen Floris Pos Evelyn Monninkhof Sjoerd G Elias Karin Haustermans Robert J Smeenk Jochem van der Voort van Zyp C édric Draulans Sofie Isebaert Petra J van Houdt Linda G W Kerkmeijer Uulke A van der Heide Source Type: research
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
CONCLUSION: The INSIGhT design enabled efficient simultaneous testing of three experimental agents using a shared control arm and adaptive randomization. Two investigational arms had superior PFS compared with the control arm, but none demonstrated an OS benefit. The INSIGhT design may promote improved and more efficient therapeutic discovery in glioblastoma. New arms have been added to the trial.PMID:37722087 | DOI:10.1200/JCO.23.00493
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Rifaquat Rahman Lorenzo Trippa Eudocia Q Lee Isabel Arrillaga-Romany Geoffrey Fell Mehdi Touat Christine McCluskey Jennifer Wiley Sarah Gaffey Jan Drappatz Mary R Welch Evanthia Galanis Manmeet S Ahluwalia Howard Colman L Burt Nabors Jaroslaw Hepel Heinri Source Type: research
Relationship between seminal vesicle displacement and distribution of hydrogel spacer within the perirectal space in prostate radiotherapy
In conclusion, SV cranial displacement was influenced by HS lateral distribution of ≥1.00 cm in the upper two slices. Therefore, when the sigmoid colon or small bowel is depressed in rectovesical excavation and SV needs to be included in the target volume, HS insertion should be performed carefully.PMID:37719041 | PMC:PMC10502802 | DOI:10.3892/mco.2023.2674
Source: Clinical Prostate Cancer - September 18, 2023 Category: Cancer & Oncology Authors: Kenji Makita Yasushi Hamamoto Hiromitsu Kanzaki Kei Nagasaki Katsuyoshi Hashine Source Type: research
Incorporating Tumor Biology to Select Patients for the Omission of Radiation Therapy
Surg Oncol Clin N Am. 2023 Oct;32(4):725-732. doi: 10.1016/j.soc.2023.05.006. Epub 2023 Jun 9.ABSTRACTAlthough adjuvant breast radiotherapy has long been a universal component of breast conservation therapy (BCT), it is now clear that "breast cancer" is a broad class of many disparate diseases with varying natural histories and risk profiles. In turn, some breast conservation patients enjoy exceedingly favorable outcomes following surgery alone. Ongoing trials seek to identify such low-risk patient populations, hypothesizing that some may safely forego radiotherapy. Whereas prior-generation trials focused on clinicopatholo...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Lior Z Braunstein Source Type: research
Analysis and prediction of liver volume change maps derived from computational tomography scans acquired pre- and post-radiation therapy
This study leverages the use of deep learning-based segmentation and biomechanical deformable image registration (DIR) to analyze and predict this relationship. Pre- and Post-EBRT imaging data were collected for 100 patients treated for HCC, CC or CRC with IMRT with prescription doses ranging from 50 to 100 Gy delivered in 10 to 28 fractions. For each patient, DIR between the portal and venous (PV) phase of a diagnostic CT scan acquired before RT planning, and a PV phase of a diagnostic CT scan acquired after the end of RT (on average 147±36 days) was performed to calculate Jacobian maps representing volume changes in the...
Source: Physics in Medicine and Biology - September 15, 2023 Category: Physics Authors: Guillaume Cazoulat Aashish C Gupta Mais M Al Taie Eugene J Koay Kristy K Brock Source Type: research
LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients
CONCLUSIONS: Subclassification of IR prostate cancer into FIR and UIR subcategories appears mandatory. For FIR patients, outcomes after BT monotherapy were acceptable. However, clinical failure after 125J-LDR-BT in UIR patients was notably increased, suggesting that BT monotherapy was less successful in this risk group. In contrast, the outcome in UIR patients after CRT was excellent.PMID:37714724 | DOI:10.1016/j.urolonc.2023.08.007
Source: Urologic Oncology - September 15, 2023 Category: Urology & Nephrology Authors: Andreas Boehle Dorothea Zywietz Irina Robrahn-Nitschke Achim Lusch Inke R K önig Source Type: research
Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer
CONCLUSION: SBRT is a safe and viable treatment option for oligoprogressive and oligorecurrent NSCLC. Patients with 0 to 2 sites had better OS and longer TNT-D compared to those with 3 to 5 lesions.PMID:37714807 | DOI:10.1016/j.cllc.2023.08.015
Source: Clinical Lung Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Maryam Ebadi Colton Ladbury Jason Liu Adam Rock Mykola Onyshchenko Victoria Villaflor Miguel Villalona-Calero Ravi Salgia Erminia Massarelli Percy Lee Terence Williams Arya Amini Source Type: research
Clinical application of magnetic resonance lymphangiography in the vascularized omental lymph nodes transfer with or without lymphaticovenous anastomosis for cancer-related lower extremity lymphedema
CONCLUSIONS: The precision evaluation of inguinal lymph nodes and lower extremities lymphatic system through MRL using VOLT can provide surgeons with a comprehensive understanding and reliable evidence for the treatment of cancer-related lower extremity lymphedema.PMID:37711785 | PMC:PMC10498210 | DOI:10.21037/qims-22-1443
Source: Hand Surgery - September 15, 2023 Category: Surgery Authors: Gechang Cheng Yingxing Duan Qin Xiong Wenguang Liu Fang Yu Liming Qing Panfeng Wu Liansheng Gong Xiaoli Li Juyu Tang Source Type: research
